Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Lisinopril 10 MG Oral Tablet

Known as: LISINOPRIL 10MG TAB,UD [VA Product], LISINOPRIL 10 mg ORAL TABLET [Lisinopril 10mg], LISINOPRIL 10 mg in 30 ORAL TABLET 
 
National Institutes of Health

Related topics

Related topics

39 relations
Aluminum OxideAngioedemaAngiotensin-Converting Enzyme Inhibitors [MoA]Calcium phosphate dibasic
Expand

Broader (1)

Angiotensin-Converting Enzyme Inhibitors

Narrower (2)

Lisinopril 10 MG Oral Tablet [Prinivil]Lisinopril 10 MG Oral Tablet [Zestril]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Design and characterization of lisinopril-loaded superparamagnetic nanoparticles as a new contrast agent for in vitro, in vivo MRI imaging, diagnose the tumors and drug delivery system
Superparamagnetic γ-Fe2O3@SiO2@lisinopril (MNPs-Lisinopril) nanoparticles are T2 and T2* negative contrast agents for magnetic… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2016
2016
Formulation Development and Evaluation of In-Situ Nasal Gel of Lisinopril Dihydrate
The present study was aimed to develop a mucoadhesive In-situgel of Lisinopril Dihydrate for improved bioavailability by… Expand
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 5
2014
2014
SPECTROPHOTOMETRIC METHOD FOR LISINOPRIL DETERMINATION USING NINHYDRIN
This paper presents a sensitive, accurate and rapid method for quantitative determination of lisinopril dihidrate (LIS) in bulk… Expand
  • figure 1
  • figure 2
  • figure 3
  • table I
  • table IV
2012
2012
Targeted catalytic inactivation of angiotensin converting enzyme by lisinopril-coupled transition-metal chelates.
A series of compounds that target reactive transition-metal chelates to somatic angiotensin converting enzyme (sACE-1) have been… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2012
2012
Stability-Indicating HPTLC Method for Simultaneous Determination of Lisinopril Anhydrate and S-Amlodipine Besylate in Pharmaceutical Dosage Form
A stability indicating high performance thin layer chromatography (HPTLC) method was developed and validated for determination of… Expand
2012
2012
Jam-A, Plasminogen and Fibrinogen Reactivity in a Case of a Lupus Erythematosus-Like Allergic Drug Reaction to Lisinopril
Background: Drug-induced lupus erythematosus is a lupus variant that resolves within days to months after withdrawal of the… Expand
  • figure 2
  • figure 1
  • table 1
Highly Cited
2007
Highly Cited
2007
Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique.
UNLABELLED This study aimed to determine the magnitude and distribution of tissue angiotensin-converting enzyme (ACE), mast-cell… Expand
  • figure 1
  • figure 2
  • figure 3
2005
2005
Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril.
Sodium depletion with diuretics augments the efficacy of angiotensin-converting enzyme-inhibitor therapy for hypertension and… Expand
Highly Cited
2000
Highly Cited
2000
Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism.
BACKGROUND Cardiac complications are the main cause of death in renal transplantation (RT), and left ventricular hypertrophy (LVH… Expand
1998
1998
The impact of beta‐receptor blocker addition to high‐dose angiotensin‐converting enzyme inhibitor‐nitrate therapy in heart failure
Background: The natural history of heart failure is one of continued worsening of cardiac function. Beta‐receptor blocker therapy… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE